CLIC researchers are located all over the world.
As of January 2023, key numbers about CLIC include:
• 6 Continents
• 19 Countries
• 40 Principal Investigators (PIs) and Designates
• ~ 50 Studies
• > 32000 leukemia cases
• > 14000 brain tumor cases
• > 16000 embryonal tumor cases
• > 3.9 million controls
• 1 Data Coordination Center
Study Locations / PIs and Designates and Their Institutions
Australia
Elizabeth Milne, PhD
Telethon Kids Institute
Nedlands, Western Australia, Australia
and
Helen Bailey, PhD
Curtin University
Perth, Western Australia, Australia
ORCID
Brazil — Multiple Studies
Maria S. Pombo-de-Oliveira, MD, PhD
Brazilian National Cancer Institute (INCA)
Rio de Janeiro, Brazil
ORCID
Victor Wünsch-Filho, PhD
University of São Paulo
São Paulo, Brazil
Karina Braga Ribeiro, DDS, PhD
Santa Casa de São Paulo School of Medical Sciences
São Paulo, Brazil
ORCID
Canada — Multiple Studies
Claire Infante-Rivard, MD, PhD
McGill University
Montréal, Québec, Canada
Denmark
Julia E. Heck, PhD
University of North Texas
Denton, Texas
ORCID
and
Johnni Hansen, PhD
Danish Cancer Society Research Center
Copenhagen, Denmark
ORCID
France — Multiple Studies
Jacqueline Clavel, MD, PhD
French National Institute of Health and Medical Research (Inserm)
Paris, France
ORCID
and
Denis Hémon, PhD
French National Institute of Health and Medical Research (Inserm)
Paris, France
ORCID
and
Audrey Bonaventure, MD, PhD
French National Institute of Health and Medical Research (Inserm)
Paris, France
ORCID
Germany
Joachim Schüz, PhD
International Agency for Research on Cancer (IARC)
Lyon, France
ORCID
and
Friederike Erdmann, PhD, MPH
University Medical Center of the Johannes Gutenberg University Mainz
Mainz, Germany
Greece
Eleni Th. Petridou, MD, PhD
National and Kapodistrian University of Athens
Athens, Greece
ORCID
and
Evangelia Ntzani, MD, PhD
University of Ioannina
Ioannina, Greece
ORCID
Italy — Multiple Studies
Marco Vinceti, MD, PhD
University of Modena and Reggio Emilia
Modena, Emilia-Romagna, Italy
ORCID
and
Tommaso Filippini, MD
University of Modena and Reggio Emilia
Modena, Emilia-Romagna, Italy
ORCID
Lucia Miligi, DSc
Institute for the Study and Prevention of Cancer (ISPRO)
Florence, Tuscany, Italy
Japan
Kevin Y. Uruyama PhD, MPH
St. Luke’s International University National Center for Child Health and Development
Tokyo, Japan
Mexico
Juan Manuel Mejía-Aranguré, PhD
National Institute of Genomic Medicine (INMEGEN)
Mexico City, Mexico
ORCID
and
Juan Carlos Núñez-Enríquez, PhD
Mexican Social Security Institute (IMSS)
Mexico City, Mexico
ORCID
New Zealand
John D. Dockerty, MBChB, DipComH, PhD
University of Otago
Dunedin, New Zealand
Sweden
Maria Feychting, PhD
Karolinska Institute
Stockholm, Sweden
and
Giorgio Tettamanti, PhD
Karolinska Institute
Stockholm, Sweden
ORCID
Taiwan
Pei-Chen Lee, PhD
Department of Public Health
National Cheng Kung University
ORCID
and
Julia E. Heck, PhD
University of North Texas
Denton, Texas
ORCID
United Kingdom — Multiple Studies
Richard McNally, PhD
Newcastle University
Newcastle upon Tyne, England, United Kingdom
ORCID
United States — Multiple Studies
Catherine Metayer, MD, PhD
University of California, Berkeley
Berkeley, California
ORCID
Joseph Wiemels, PhD
University of Southern California
Los Angeles, California
and
Xiaomei Ma, PhD
Yale University
New Haven, Connecticut
Erin Marcotte, PhD
University of Minnesota, Twin Cities
Minneapolis, Minnesota
ORCID
and
Logan G. Spector, PhD
University of Minnesota, Twin Cities
Minneapolis, Minnesota
ORCID
Michael E. Scheurer, PhD, MPH
Baylor College of Medicine
Texas Children’s Hospital
Houston, Texas
ORCID
and
Philip J. Lupo, PhD
Baylor College of Medicine
Houston, Texas
ORCID
Beth A. Mueller, DrPH
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
ORCID